“ION continues to focus on collaborating with healthcare systems to provide quality patient care with excellent clinical outcomes”, said Jeffrey Goffman, Chief Executive Officer of ION.
OVERLAND PARK, Kan. December 18, 2017
Addition of Saint Luke’s South Hospital Radiation Center completes final piece of comprehensive oncology service in Johnson County
Integrated Oncology Network, LLC (“ION”) and Saint Luke’s Cancer Institute, in conjunction with Saint Luke’s South Hospital, announced their formal collaboration with ION’s radiation oncology facility located in Overland Park, Kansas.
The affiliation between ION and Saint Luke’s represents an alignment of commitment to high quality, patient-centered care and provides comprehensive care to all oncology patients throughout the Kansas City metro area.
“ION continues to focus on collaborating with healthcare systems to provide quality patient care with excellent clinical outcomes. ION is honored to partner with Saint Luke's South Hospital of Kansas City, who has continued to demonstrate its commitment to a comprehensive oncology program for the patients in Kansas City,” said Jeffrey Goffman, Chief Executive Officer of ION.
“A cancer diagnosis is extremely stressful for patients and their families. Saint Luke’s Cancer Institute is committed to providing the full range of oncology services close to home for our patients,” said Timothy Pluard, M.D., Saint Luke’s Cancer Institute Medical Director. “The addition of the Saint Luke’s South Radiation Center is the final piece in being able to say we truly provide comprehensive care to all our cancer patients regardless of where they live in Kansas City.”
“Saint Luke's South Hospital is pleased to expand our cancer treatment service line,” said Robert Olm-Shipman, Chief Executive Officer. “This collaboration delivers on our ongoing commitment to provide the very best medical care to our patients in Johnson County.”
The Saint Luke’s South Radiation Center, located at 6427 W. 119th Street, Overland Park, KS, will commence clinical services on January 2, 2018. The Center will give patients local access to leading-edge technology from Varian, including Intensity-Modulated Radiation Therapy (IMRT), Image-Guided Radiation Therapy (IGRT) and Stereotactic Radiosurgery (SRS)/Stereotactic Body Radiotherapy (SBRT).
About Saint Luke’s Health System
Saint Luke’s Health System consists of 10 area hospitals and campuses, and several primary and specialty care practices, and provides a range of inpatient, outpatient, and home care services. Founded as a faith-based, not-for-profit organization, our mission includes a commitment to the highest levels of excellence in health care and the advancement of medical research and education. The health system is an aligned organization in which the physicians and hospitals assume responsibility for enhancing the physical, mental, and spiritual health of people in the metropolitan Kansas City area and the surrounding region.
Integrated Oncology Network Holdings, LLC and its subsidiaries (“ION”) is a radiation oncology management and cancer center development company that partners with hospitals and physicians that seek management expertise. ION provides strategic solutions, development for cancer centers, financing and management services with expertise in radiation oncology operations including revenue cycle & compliance. For more information on ION, please visit our web site at http://www.ion-llc.com.
Statements in this Press Release that are not historical facts constitute “forward-looking statements.” Any statements contained herein which are not historical facts or which contain the words “anticipate,” “believe,” “continue,” “estimate,” “expect,” “intend,” “may,” “should,” and similar expressions are intended to identify forward-looking statements. Such statements reflect the current view of ION with respect to future events and are subject to certain risks, uncertainties and assumptions, including, but not limited to, the risk that ION may not be able to implement its growth strategy in the intended manner, including the ability to identify, finance, complete joint venture opportunities, risks regarding currently unforeseen competitive pressures and risks affecting ION’s industry, such as increased regulatory compliance and changes in regulatory requirements, changes in payor reimbursement levels. Should one or more of those risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described herein.
Latest posts by Brad Bennett (see all)
- MediciNova Announces Upcoming Presentation of the SPRINT-MS Phase 2b Trial of MN-166 (ibudilast) in Progressive MS at the American Academy of Neurology (AAN) 70th Annual Meeting in Los Angeles, California - February 18, 2018
- Mario Lopez Announced As Host To The 'Splash of Love' Gala Fundraiser At Proud Bird Food Bazaar & Events Center - February 18, 2018
- Oxnard Teen, Skilled Boxer Honored as BGCOP's Youth of the Year - February 18, 2018